Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and eval ...

Sagimet Biosciences eyes major opportunities in MASH and Acne treatments. Find out why SGMT stock is a solid pick with ...

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...

The EFTISARC-NEO trial, with a data cut-off of 20 October 2024, also showed 71.4% of patients achieved a pathologic response ...

GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch in ...

Endpoint Detection and Response (EDR) firm Cybereason and managed security services provider (MSSP) Trustwave announced plans to merge.

N4 Architecture talks about the design of its Birch Pavilion, which provides a space for work, relaxation and listening to ...

"We offer MSPs a layer of value with secure, modern endpoint management, powered by both Microsoft Intune and Devicie and we ...

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.

Kaseya VSA offers several monitoring and patch management functions, making it a complete RMM platform. You get the benefits ...

ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) — Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center, ...